561297-96-9

Basic information

• Product Name: 2-Pyridinemethanamine,5-fluoro-(9CI)
• Synonyms: 2-Pyridinemethanamine,5-fluoro-(9CI);5-Fluoro-2-pyridinemethanamine;5-fluoro-(9CI)2-Pyridinemethanamine;C-(5-Fluoro-pyridin-2-yl)-MethylaMine;2-(AMinoMethyl)-5-fluoropyridine;1-(5-FLUOROPYRIDIN-2-YL)METHANAMINE HYDROCHLORIDE;2-Pyridinemethanamine, 5-fluoro-
• CAS NO: 561297-96-9
• Molecular Formula: C₆H₇FN₂
• Molecular Weight: 126.133
• Product Categories: PYRIDINE
• Mol File: 561297-96-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 181.563 °C at 760 mmHg
• Flash Point: 63.607 °C
• Appearance: /
• Density: 1.18 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.30±0.39(Predicted)
• CAS DataBase Reference: 2-Pyridinemethanamine,5-fluoro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinemethanamine,5-fluoro-(9CI)(561297-96-9)
• EPA Substance Registry System: 2-Pyridinemethanamine,5-fluoro-(9CI)(561297-96-9)

Safety Data

• Hazardous Substances Data: 561297-96-9(Hazardous Substances Data)

Usage

General Description

2-Pyridinemethanamine, 5-fluoro-(9CI) is a chemical compound with the molecular formula C6H7FN. It is a derivative of pyridine with a fluorine atom substituted at the 5-position. 2-Pyridinemethanamine,5-fluoro-(9CI) is used in pharmaceutical research as a potential building block for the synthesis of various biologically active compounds. It may also have potential applications in organic synthesis and medicinal chemistry due to its fluorinated structure, which can impart desirable properties to the resulting molecules. However, further research is needed to fully understand its potential uses and properties.

Upstream product

• 1159252-09-1 1-(5-fluoropyridin-2-yl)-N-hydroxymethanimine 
• 31181-88-1 5-fluoropicolinaldehyde 
• 1228788-31-5 diethyl (5-fluoro-2-pyridyl)-2-acetamidomalonate 
• 327056-62-2 5-fluoropicolinonitrile 

Downstream Products

• 1418283-51-8 N-[(5-fluoropyridin-2-yl)methyl]-2-(2,4-dichlorophenoxy)propanamide 
• 1450633-67-6 rac-(2-(aminomethyl)-5-fluoropiperidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone 
• 1450633-66-5 tert-butyl(5-fluoropiperidin-2-yl)methylcarbamate 
• 1450633-65-4 tert-butyl(1-benzyl-5-fluoro-1,2,3,4-tetrahydropyridin-2-yl)methylcarbamate 
• 1450633-64-3 1-benzyl-2-((tert-butoxycarbonylamino)methyl)-5-fluoropyridiniumbromide 
• 1383481-98-8 (5-fluoro-2-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)piperidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone 
• 1450634-39-5 tert-butyl (5-fluoro-1-(2-methyl-5-phenylthiazole-4-carbonyl)piperidin-2-yl)methylcarbamate 
• 1429939-76-3 C₂₁H₁₉F₄N₅O 

Relevant articles and documents

4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I , or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof